In contrast, all AH samples from RB patients exhibited CD63/81 dominance compared to CD9 enrichment levels, consistent with our previous SP-IRIS research, further validating the outcomes obtained through the new MACSPlex workflow. This evidence concerns the gene CD9 and retinoblastoma.